---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-059569"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T04:25:01.904360+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens

## Summary
- Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.
- Adjusted operating income $23M, up 72% YoY; adjusted gross margin 53.7% vs 49.2%.
- Orders grew high-teens YoY with all four franchises up double-digits; biopharma and consumables record ex-COVID.
- FY2025 guidance reiterated: organic growth 9.5%-13.5%; adjusted EPS $1.63-$1.72.
- Closed acquisition of 908 Devices' bioprocessing portfolio; minimal tariff impact expected.

## SEC filing metadata
- accession: 0000950170-25-059569
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000095017025059569/0000950170-25-059569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000095017025059569/rgen-20250429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-059569
- JSON: https://secwatch.observer/filing/0000950170-25-059569.json
- Plain text: https://secwatch.observer/filing/0000950170-25-059569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.